SE9800550D0 - A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof - Google Patents

A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof

Info

Publication number
SE9800550D0
SE9800550D0 SE9800550A SE9800550A SE9800550D0 SE 9800550 D0 SE9800550 D0 SE 9800550D0 SE 9800550 A SE9800550 A SE 9800550A SE 9800550 A SE9800550 A SE 9800550A SE 9800550 D0 SE9800550 D0 SE 9800550D0
Authority
SE
Sweden
Prior art keywords
angiotensin
type
receptor agonist
pharmaceutical preparation
dyspepsia
Prior art date
Application number
SE9800550A
Other languages
Swedish (sv)
Inventor
Lars Faendriks
Anders Pettersson
Anders Hallberg
Original Assignee
A & Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & Science Invest Ab filed Critical A & Science Invest Ab
Priority to SE9800550A priority Critical patent/SE9800550D0/en
Publication of SE9800550D0 publication Critical patent/SE9800550D0/en
Priority to IDW20001909A priority patent/ID26639A/en
Priority to KR1020007009295A priority patent/KR20010041211A/en
Priority to MXPA00008172A priority patent/MXPA00008172A/en
Priority to CA002319123A priority patent/CA2319123A1/en
Priority to AU27537/99A priority patent/AU755949B2/en
Priority to EEP200000481A priority patent/EE200000481A/en
Priority to EP99908017A priority patent/EP1066048A1/en
Priority to NZ506188A priority patent/NZ506188A/en
Priority to JP2000533135A priority patent/JP2002504516A/en
Priority to BR9908188-1A priority patent/BR9908188A/en
Priority to PCT/SE1999/000262 priority patent/WO1999043339A1/en
Priority to CN99803230A priority patent/CN1291104A/en
Priority to HU0101411A priority patent/HUP0101411A3/en
Priority to SK1152-2000A priority patent/SK11522000A3/en
Priority to IL13799099A priority patent/IL137990A0/en
Priority to IS5594A priority patent/IS5594A/en
Priority to NO20004215A priority patent/NO20004215L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, which can be either a peptide or a peptide mimetic, said preparation being useful for treatment and prophylaxis of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure. Use of an angiotensin II type 2 receptor agonist for the manufacture of a medicament for treatment and/or prophylaxis of disorder of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure. A method for treatment and/or prevention of a condition selected from the group consisting of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure in a patient, wherein an effective amount of an angiotensin II type 2 receptor agonist is administered to the patient.
SE9800550A 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof SE9800550D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE9800550A SE9800550D0 (en) 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
IL13799099A IL137990A0 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
NZ506188A NZ506188A (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
BR9908188-1A BR9908188A (en) 1998-02-24 1999-02-24 Pharmaceutical preparation, use of an angiotensin ii type 2 receptor agonist or a physiologically acceptable salt thereof, and process for treating and / or preventing a condition selected from the group consisting of disorders of the alimentary tract, such as dyspepsia, syndrome irritable bowel and / or multiple organ failure in a patient
MXPA00008172A MXPA00008172A (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof.
CA002319123A CA2319123A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
AU27537/99A AU755949B2 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
EEP200000481A EE200000481A (en) 1998-02-24 1999-02-24 A pharmaceutical preparation containing angiotensin II type 2 receptor agonist and its use
EP99908017A EP1066048A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
IDW20001909A ID26639A (en) 1998-02-24 1999-02-24 PHARMACEUTICAL PROPERTIES THAT CONTAIN ANGIOTENSIN II RECEPTOR AGONISTS, TYPE 2 AND ITS USE
JP2000533135A JP2002504516A (en) 1998-02-24 1999-02-24 Pharmaceutical formulations containing angiotensin II type 2 receptor agonists and uses thereof
KR1020007009295A KR20010041211A (en) 1998-02-24 1999-02-24 A Pharmaceutical Preparation Comprising an Angiotensin II Type 2 Receptor Agonist, and Use Thereof
PCT/SE1999/000262 WO1999043339A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
CN99803230A CN1291104A (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotension II2 type receptor agonist, and use thereof
HU0101411A HUP0101411A3 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
SK1152-2000A SK11522000A3 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
IS5594A IS5594A (en) 1998-02-24 2000-08-21 A pharmaceutical composition containing an angiotensin II receptor type 2 receptor agonist and its use
NO20004215A NO20004215L (en) 1998-02-24 2000-08-23 A pharmaceutical composition comprising an angiotensin II type 2 receptor agonist, and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9800550A SE9800550D0 (en) 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof

Publications (1)

Publication Number Publication Date
SE9800550D0 true SE9800550D0 (en) 1998-02-24

Family

ID=20410283

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9800550A SE9800550D0 (en) 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof

Country Status (18)

Country Link
EP (1) EP1066048A1 (en)
JP (1) JP2002504516A (en)
KR (1) KR20010041211A (en)
CN (1) CN1291104A (en)
AU (1) AU755949B2 (en)
BR (1) BR9908188A (en)
CA (1) CA2319123A1 (en)
EE (1) EE200000481A (en)
HU (1) HUP0101411A3 (en)
ID (1) ID26639A (en)
IL (1) IL137990A0 (en)
IS (1) IS5594A (en)
MX (1) MXPA00008172A (en)
NO (1) NO20004215L (en)
NZ (1) NZ506188A (en)
SE (1) SE9800550D0 (en)
SK (1) SK11522000A3 (en)
WO (1) WO1999043339A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
WO2001043761A2 (en) * 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing damage to mucosal tissue
ES2295339T3 (en) 2001-05-31 2008-04-16 Vicore Pharma Ab USEFUL TRICILICAL COMPOUNDS AS AGONISTS OF ANGIOTENSIN II.
ES2384450T3 (en) 2005-04-12 2012-07-05 Vicore Pharma Ab NEW AGONISTS OF ANGIOTENSIN II TRICLIQUE.
MX2007012633A (en) 2005-04-12 2008-01-11 Vicore Pharma Ab New bicyclic angiotensin ii agonists.
JP5202301B2 (en) 2005-04-12 2013-06-05 ヴィコール・ファルマ・アーベー Novel tricyclic angiotensin II agonist
CA2882445A1 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
WO2013158628A1 (en) * 2012-04-16 2013-10-24 New York University Modulation of angiotensin ii peceptors for the prevention and treatment of cerebral malaria
AU2016227486A1 (en) 2015-03-02 2017-08-17 Vicore Pharma Ab Angiotensin ll receptor agonist for treating pulmonary fibrosis
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
EP4007592A1 (en) 2019-08-02 2022-06-08 LanthioPep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
IL296247A (en) 2020-03-19 2022-11-01 Vicore Pharma Ab Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii
GB202004094D0 (en) 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006081D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202013721D0 (en) 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
CA3212900A1 (en) 2021-03-23 2022-09-29 Tomas Fex Selective angiotensin ii receptor ligands
GB202104038D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB202104033D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
CA3222721A1 (en) 2021-07-09 2023-01-12 Nadia Nasser PETERSEN New selective angiotensin ii compounds
GB202115303D0 (en) 2021-10-25 2021-12-08 Vicore Pharma Ab New formulation
WO2023152503A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444067A (en) * 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
WO1996014060A1 (en) * 1994-11-04 1996-05-17 Marklund Stefan L Use of receptor agonists to stimulate superoxide dismutase activity
SE9501881D0 (en) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII receptor antagonists
US5834432A (en) * 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
SE9502219D0 (en) * 1995-06-19 1995-06-19 Astra Ab Novel medical use

Also Published As

Publication number Publication date
EE200000481A (en) 2002-02-15
NO20004215L (en) 2000-09-18
CN1291104A (en) 2001-04-11
BR9908188A (en) 2000-10-24
KR20010041211A (en) 2001-05-15
MXPA00008172A (en) 2002-06-21
ID26639A (en) 2001-01-25
NO20004215D0 (en) 2000-08-23
WO1999043339A1 (en) 1999-09-02
JP2002504516A (en) 2002-02-12
EP1066048A1 (en) 2001-01-10
IS5594A (en) 2000-08-21
SK11522000A3 (en) 2001-04-09
HUP0101411A3 (en) 2002-11-28
IL137990A0 (en) 2001-10-31
AU2753799A (en) 1999-09-15
CA2319123A1 (en) 1999-09-02
NZ506188A (en) 2003-04-29
HUP0101411A2 (en) 2002-03-28
AU755949B2 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
SE9800550D0 (en) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
EA200501496A1 (en) HIGH-SELECTIVE INHIBITORS OF REVERSE CAPTURE OF NOREPINEFRIN AND METHODS OF THEIR APPLICATION
ATE204178T1 (en) METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN
Rabinowitz et al. The effect of clozapine on saliva flow rate: a pilot study
DK0893992T3 (en) Rapidly decomposing oral dosage form
FI964332A (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
RU2220723C2 (en) Agent and method for treatment or prophylaxis of arteriosclerosis
BR9908030A (en) Pharmaceutical composition comprising one or more orally administered dose units, and processes for preparing it, for use thereof, and for treating a medical condition or disorder in an individual in whom treatment with a cyclooxygenase-2 inhibitor is indicated
BG101118A (en) Therapeutical compounds
HUP9904362A2 (en) Treatment of upper airway allergic responses with a combination of histamine h1 and h3 receptor antagonists
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
Baird et al. Non-antibiotic anti-diarrhoeal drugs: Factors affecting oral bioavailability of berberine and loperamide in intestinal tissue
RU2218917C2 (en) Application of specific antagonist of 5ht2a-receptors for preparing drugs useful for treatment of sleep apnea syndrome
JP2004537500A5 (en)
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
BRPI0412430A (en) zot and zonulin receptor agonist polypeptide
JP2002519391A5 (en)
BR0107960A (en) Treatment of allergic and inflammatory conditions
Klawans et al. Neuroleptic-induced tardive dyskinesias in nonpsychotic patients
CA2433785A1 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
DK0866711T3 (en) Use of 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamide for the preparation of a pharmaceutical composition for the prevention of sleep apnea
EP0744176A3 (en) Methods for inhibiting bone loss
SE9902597D0 (en) New use
Stancic-Rokotov et al. Ethanol gastric lesion aggravated by lung injury in rat. Therapy effect of antiulcer agents
HK1026843A1 (en) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x.